tbuckley/cabot-search huggingface dataset:
FAM198B Is Associated with Prolonged Survival and Inhibits Metastasis in Lung Adenocarcinoma via Blockage of ERK-Mediated MMP-1 Expression
Authors: Chia-Ying Hsu, Gee-Chen Chang, Yi-Ju Chen, Yi-Chiung Hsu, Yi-Jing Hsiao, Kang-Yi Su, Hsuan-Yu Chen, Chien-Yu Lin, Jin-Shing Chen, Yu-Ju Chen, Qi-Sheng Hong, Wen-Hui Ku, Chih-Ying Wu, Bing-Ching Ho, Ching-Cheng Chiang, Pan-Chyr Yang, Sung-Liang Yu
Journal: Clinical Cancer Research (2017)

Purpose: The comprehensive understanding of mechanisms involved in the tumor metastasis is urgently needed for discovering novel metastasis-related genes for developing effective diagnoses and treatments for lung cancer.Experimental Design: FAM198B was identified from an isogenic lung cancer metastasis cell model by microarray analysis. To investigate the clinical relevance of FAM198B, the FAM198B expression of 95 Taiwan lung adenocarcinoma patients was analyzed by quantitative real-time PCR and correlated to patients' survivals. The impact of FAM198B on cell invasion, metastasis, and tumor growth was examined by in vitro cellular assays and in vivo mouse models. In addition, the N-glycosylation-defective FAM198B mutants generated by site-directed mutagenesis were used to study protein stability and subcellular localization of FAM198B. Finally, the microarray and pathway analyses were used to elucidate the underlying mechanisms of FAM198B-mediated tumor suppression.Results: We found that the high expression of FAM198B was associated with favorable survival in Taiwan lung adenocarcinoma patients and in a lung cancer public database. Enforced expression of FAM198B inhibited cell invasion, migration, mobility, proliferation, and anchorage-independent growth, and FAM198B silencing exhibited opposite activities in vitro FAM198B also attenuated tumor growth and metastasis in vivo We further identified MMP-1 as a critical downstream target of FAM198B. The FAM198B-mediated MMP-1 downregulation was via inhibition of the phosphorylation of ERK. Interestingly deglycosylation nearly eliminated the metastasis suppression activity of FAM198B due to a decrease of protein stability.Conclusions: Our results implicate FAM198B as a potential tumor suppressor and to be a prognostic marker in lung adenocarcinoma. Clin Cancer Res; 24(4); 916-26. ©2017 AACR.
Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells
Authors: Yukari Muguruma, Takashi Yahata, Takayuki Warita, Katsuto Hozumi, Yoshihiko Nakamura, Rikio Suzuki, Mamoru Ito, Kiyoshi Ando
Journal: Blood Cancer Journal (2017)
Mir-424 and Mir-503 Regulates Cobll1 Expression during the CML Progression
Authors: Seung Hun Han, Soo-Hyun Kim, Kim Hyoung-June, Lee Yoonsung, Soo-Young Choi, Park Gyeongsin, Kim Do-Hyun, Lee Aram, Kim Jongmin, Choi Je-Min, Kim Yonghwan, Myung Kyungjae, Kim Hongtae, Dong-Wook Kim
Journal: Blood (2017)
Trends in Hospital Cost, Length of Stay, Complication Rates, and Mortality in Patients with Acute Lymphoblastic Leukemia in Teaching Versus Nonteaching Institutions: Data from the Nationwide Inpatient Sample from 1999-2014
Authors: Erika Correa, Stuthi Perimbeti, Mariola Vazquez-Martinez, William Lee, Kristine Ward, Michael Styler, Maneesh Jain
Journal: Blood (2017)
Exacerbation of Aging‐Associated and Instability‐Induced Murine Osteoarthritis With Deletion of D Prostanoid Receptor 1, a Prostaglandin D<sub>2</sub> Receptor
Authors: Yassine Ouhaddi, Sarah‐Salwa Nebbaki, Lauris Habouri, Hassan Afif, Bertrand Lussier, Mohit Kapoor, Shuh Narumiya, Jean‐Pierre Pelletier, Johanne Martel‐Pelletier, Mohamed Benderdour, Hassan Fahmi
Journal: Arthritis & Rheumatology (2017)

Objective D prostanoid receptor 1 (DP1), a receptor for prostaglandin D 2 , plays important roles in inflammation and cartilage metabolism. However, its role in the pathogenesis of osteoarthritis (OA) remains unknown. This study was undertaken to explore the roles of DP1 in the development of OA in murine models and to evaluate the efficacy of a DP1 selective agonist in the treatment of OA. Methods The development of aging‐associated OA and destabilization of the medial meniscus (DMM)–induced OA was compared between DP1‐deficient (DP1 −/− ) and wild‐type (WT) mice. The progression of OA was assessed by histology, immunohistochemistry, and micro–computed tomography. Cartilage explants from DP1 −/− and WT mice were treated with interleukin‐1α (IL‐1α) ex vivo, to evaluate proteoglycan degradation. The effect of intraperitoneal administration of the DP1 selective agonist BW245C on OA progression was evaluated in WT mice. Results Compared to WT mice, DP1 −/− mice had exacerbated cartilage degradation in both models of OA, and this was associated with increased expression of matrix metalloproteinase 13 and ADAMTS‐5. In addition, DP1 −/− mice demonstrated enhanced subchondral bone changes. Cartilage explants from DP1 −/− mice showed enhanced proteoglycan degradation following treatment with IL‐1α. Intraperitoneal injection of BW245C attenuated the severity of DMM‐induced cartilage degradation and bony changes in WT mice. Conclusion These findings indicate a critical role for DP1 signaling in OA pathogenesis. Modulation of the functions of DP1 may constitute a potential therapeutic target for the development of novel OA treatments.
Noninvasive small-animal imaging of galectin-1 upregulation for predicting tumor resistance to radiotherapy
Authors: Jianhao Lai, Dehua Lu, Chenran Zhang, Hua Zhu, Liquan Gao, Yanpu Wang, Rui Bao, Yang Zhao, Bing Jia, Fan Wang, Zhi Yang, Zhaofei Liu
Journal: Biomaterials (2017)
La triquinosis sigue siendo un problema en Europa
Authors: J Dupouy-Camet
Journal: Eurosurveillance (2006)

La triquinosis es una enfermedad zoonotica debida al consumo de carne cruda que contiene larvas del nematodo Trichinella. En Europa hay cuatro especies de triquinas : Trichinella spiralis (especie cosmopolita), T. britovi (en la fauna salvaje de montanas), T. nativa (animales salvajes de regiones mas frias y nordicas) y T. pseudospiralis (una especie no encapsulada cosmopolita). La triquinosis humana produce fiebre muy alta, edema facial, miositis y eosinofilia. Puede ser una enfermedad grave, especialmente en personas mayores en las cuales las complicaciones neurologicas o cardiovasculares pueden causar la muerte.
Incidence and Risk Factors for Venous Thrombosis in Human Immunodeficiency Virus (HIV) Infection, Data from the Dutch Athena Cohort Study
Authors: James Francis Borjas-Howard, Casper Rokx, Colette Smit, Ferdinand Wit, Elise Pieterman, Karina Meijer, Bart Rijnders, Wouter Bierman, Vladimir Tichelaar
Journal: Blood (2016)
Abstract 11686: Pericellular Amyloid Infiltration in Biopsy-proven Cardiac Amyloidosis
Authors: Tetsuro Yokokawa, Yasuo Sugano, Taka-aki Matsuyama, Kanzaki Hideaki, Keiko Ohta-Ogo, Yoshihiko Ikeda, Hatsue Ishibashi-Ueda, Yasuchika Takeishi, Satoshi Yasuda, Toshihisa Anzai
Journal: Circulation (2016)

Background: Cardiac amyloidosis is a rare disease characterized by the myocardial infiltration of amyloid. There are several histopathological patterns of amyloid accumulation, of which pericellular amyloid pattern is classified when amyloid is observed around each cardiomyocyte in endomyocardial biopsy. However, the relationship between pericellular amyloid deposition pattern and clinical characteristics has not yet been investigated. Objective: We retrospectively investigated endomyocardial biopsy-proven cardiac amyloidosis with pericellular amyloid deposition. Methods: Thirty cardiac amyloidosis patients in our institution were included. Results: Thirteen patients (43%) were pathologically classified into pericellular amyloid deposition. In the baseline characteristics, the patients with pericellular deposition had significantly lower age (69 ± 9 vs. 75 ± 6 years, p = 0.032) and higher brain natriuretic peptide levels (681 ± 516 vs. 267 ± 393 pg/ml, p = 0.003), compared with those without pericellular deposition. Electrocardiographic findings revealed that patients with pericellular amyloid deposition had significantly higher incidence of low voltage (46 vs. 12%, p = 0.045) and pseudoinfarction pattern (46 vs. 6%, p = 0.015), compared with patients without pericellular deposition. Echocardiography revealed that patients with pericellular deposition had significantly decreased deceleration time (152 ± 49 vs. 191 ± 50 ms, p = 0.049). Hemodynamic findings did not show significant difference between groups. High-sensitivity cardiac troponin-T levels were also analyzed in 14 cardiac amyloidosis patients without ischemic heart disease. Patients with pericellular amyloid deposition had significantly higher high-sensitivity cardiac troponin-T levels, compared with patients without pericellular deposition (0.128 ± 0.07 vs. 0.046 ± 0.03 pg/ml, p = 0.016). Conclusion: Pericellular amyloid deposition pattern was associated with electrocardiographic abnormalities, diastolic dysfunction, and ongoing myocardial damage. Our data suggest direct amyloid infiltration around the cardiomyocytes may cause myocardial damage, providing possible pathophysiological implication of the failing heart in cardiac amyloidosis.
Value of Myocardial Perfusion Assessment With Coronary Computed Tomography Angiography in Patients With Recent Acute-Onset Chest Pain
Authors: Mathias H. Sørgaard, Jesper J. Linde, J. Tobias Kühl, Henning Kelbæk, Jens D. Hove, Gitte G. Fornitz, Tem B.S. Jørgensen, Merete Heitmann, Charlotte Kragelund, Thomas F. Hansen, Jawdat Abdulla, Thomas Engstrøm, Jan S. Jensen, Yaffah T. Wiegandt, Dan E. Høfsten, Lars V. Køber, Klaus F. Kofoed
Journal: JACC. Cardiovascular imaging (2017)
Visa problems mean NHS is losing UK trained GPs, doctors warn
Authors: Abi Rimmer
Journal: BMJ (2017)

The NHS is losing GPs from overseas who have trained in the UK, because of difficulties and delays in applying for visas, doctors have warned.

Last month the House of Commons Health Committee put out a call for examples of cases where GPs from outside the European Economic Area had been unable to work or had been forced to leave the UK because of visa problems.1

In August NHS England announced that it would aim to employ 600 GPs from overseas in 2017-18 and “at least” 2000 doctors from overseas by 2020-21. The NHS will spend £100m (€110m; $130m) on agency fees over the next three years to recruit these doctors.2

Despite these ambitions, figures shared with The BMJ in July showed that only 38 GPs had been recruited through the International GP Recruitment Programme.3

John Coffey, a GP and training programme director from Lincolnshire, said it was frustrating that the NHS was actively recruiting GPs overseas when GPs who trained in the …
Extra cash for child mental health is being diverted, report warns
Authors: Gareth Iacobucci
Journal: BMJ (2017)

Extra government investment in child and adolescent mental health services is being used to plug gaps in other services in many areas of the country and is failing to reach the front line, a report into children’s health has warned.1

The report from the Children’s Rights Alliance for England said that half of clinical commissioning groups were using extra money for child and adolescent mental health services to fund other services because it has not been ringfenced. This was causing variation in access and waiting times around the country, while numbers of cases of suicide and self harm among children were increasing at “alarming rates,” the charity warned.

The alliance expressed particular concern at …
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303).
Authors: Scott G. Williams, Ian D. Davis, Christopher Sweeney, Martin R. Stockler, Andrew James Martin, Vittorio Marchesin, Olwyn Deignan, Ray McDermott, Anne Poh Long, Felicia T Roncolato, Sonia Yip, Wendy Hague, Emily Tu, Xanthi Coskinas, Paul Linh Nguyen
Journal: Journal of Clinical Oncology (2015)

TPS5078 Background: Adjuvant androgen deprivation therapy (ADT) including a luteinising hormone releasing hormone analogue (LHRHA) is standard of care given before, during, and after radiotherapy for localised prostate cancer (PC) at high risk of recurrence. Enzalutamide is a new, second generation androgen receptor (AR) inhibitor that is more potent and binds with a higher affinity to the AR than conventional non-steroidal anti-androgens (NSAA), and improves survival in metastatic, castration-resistant PC. We hypothesise that the incorporation of enzalutamide in adjuvant ADT, given before, during, and after radiation therapy for localised PC at high risk of recurrence will further improve outcomes.The aim is to determine the effectiveness of enzalutamide as part of adjuvant ADT with a LHRHA in men planned for radiotherapy for localised PC at high risk of recurrence Methods: DESIGN Open label, randomised, stratified, 2-arm, phase 3 intergroup trial. ELIGIBILITY Localised PC, high risk of recurrence, suitable for EBRT with curative intent. STRATIFICATION Gleason 8-10, T3-4, PSA > 20, study site ENDPOINTS Overall survival (primary), cause-specific survival, PSA progression free survival (PFS), clinical PFS, health related quality of life, adverse events, cost-effectiveness. SAMPLE SIZE 800 participants accrued over 2 yrs + 5.5 years minimum f/up for 80% power to detect a 33% reduction in the hazard of death assuming a 5-year survival rate of 76% amongst controls. TREATMENT LHRHA for 24 months and EBRT (78Gy/39F) starting after week 16 plus either enzalutamide 160mg daily during months 1-24, or conventional NSAA during months 1-6. ASSESSMENTS Baseline, weeks 4, 12, 16, 20 and 24, then 3-4 monthly until year 5, 6-monthly until year 7, then annually. Imaging at baseline and then as clinically indicated. Tertiary correlative objectives include the identification of prognostic and predictive biomarkers from archival tumour tissue, and from fasting bloods collected at baseline, 24 weeks, 5 years, and first evidence of progression. Email: enzarad@ctc.usyd.edu.au Website: http://www.anzup.org.au/ Clinical trial information: ACTRN12614000126617.
Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions
Authors: Nanette K. Wenger
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Mini-review on initiatives to interfere with the propagation and clearance of alpha-synuclein in Parkinson’s disease
Authors: Daniel Kam Yin Chan, Ying Hua Xu, Luke Kar Man Chan, Nady Braidy, George D. Mellick
Journal: Translational Neurodegeneration (2017)

In this mini-review, we summarize recent findings relating to the prion-like propagation of α-synuclein (α-syn) and the development of novel therapeutic strategies to target synucleinopathy in Parkinson's disease (PD). We link the Braak's staging hypothesis of PD with the recent evidence from in-vivo and in-vitro studies for the prion-like cell-to-cell propagation of α-syn (via exocytosis and endocytosis). The classical accumulation of aggregated α-syn in PD may result from an increased production or a failure in the mechanisms of clearance of α-syn. We discuss novel agents, currently in clinical trial for PD including the ones that impact the aggregation of α-syn and others that interfere with α-syn endocytosis as a means to target the progression of the disease.
Asthma control and action plans
Authors: Israel Amirav, Michael T. Newhouse
Journal: European Respiratory Journal (2017)

Asthma action plans should not cause confusion for patients by incorporating the concept of "acute loss of control" <http://ow.ly/nY1R30fDFC6> Kouri et al. [1] in Canada have developed a tool to guide completion of asthma action plans (AAPs). In their rationale, they suggest that "fewer than 25% of patients receive an AAP, partly due to prescribers' inability to complete 'yellow zone' instructions (how to intensify therapy for acute loss of control)". The authors "reviewed recent asthma guidelines and adult studies addressing acute loss of asthma control" and "developed evidence-based rules for yellow zone therapy and operational guidelines to maximise adherence and minimise errors".
Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis
Authors: Jonas Söderholm, Charlotta Millbourn, Katharina Büsch, Jan Kövamees, Robert Schvarcz, Karin Lindahl, Annette Bruchfeld
Journal: Journal of Hepatology (2017)

Several studies have shown that chronic hepatitis C (CHC) infection has a negative impact on kidney function, as well as survival, in patients with chronic kidney disease (CKD) or on hemodialysis. The aim of this nationwide registry study was to describe renal disease in Swedish patients with CHC.In the present study, patients were identified for CHC (B18.2) and CKD (N18) according to the International Classification of Diseases (ICD)-10 in the nationwide Swedish inpatient care day surgery (1997-2013) and non-primary outpatient care (2001-2013) patient registries. Hemodialysis was defined using the procedure code in the non-primary outpatient care. For each patient, up to five non-CHC diagnosed age/sex/place of residency-matched comparators were drawn from the general population at the time of diagnosis. Follow-up started at the date of CHC diagnosis and patients accrued person-time until, whichever came first, death, emigration or December 31st, 2013.Between 2001 and 2013, 42,522 patients received a CHC diagnosis. Of these patients, 2.5% (1,077/45,222) were diagnosed with CKD during 280,123 person-years, compared with 0.7% (1,454/202,694) in the matched general population comparators (1,504,765 person-years), resulting in a standardized incidence ratio (SIR) of 4.0. There was a 3.3-7.0-fold risk of patients with CHC requiring hemodialysis. Overall, 17% of patients with CHC receiving hemodialysis were treated for CHC; 24% in the treated cohort died compared with 56% of the untreated cohort (p <0.0001), with antiviral treatment improving survival with an odds ratio of 3.901 (p = 0.001).The results from this nationwide registry study showed that patients with CHC are at a higher risk of developing CKD. Furthermore, hepatitis C treatment seemed to improve survival for patients with CHC on hemodialysis compared with untreated patients.Hepatitis C is an infectious disease that mainly infects the liver, but has also been shown to have negative effects on other organs. This nationwide study demonstrates an increased risk of hepatitis C patients developing reduced kidney function and the need for dialysis. The study also showed improved survival in dialysis patients who received antiviral treatment.
Health-related quality of life in mechanically ventilated Australasian survivors of H1N1 influenza is comparable to population norms one year following discharge
Authors: Elizabeth Skinner, Kimberley Haines, Belinda Duval Howe, Carol Lynette Hodgson, Linda Denehy, Colin McArthur, Daniel Seller, Emma DiMarco, Kate Mulvaney, Danielle Ryan, Sue Berney
Journal: American Journal of Respiratory and Critical Care Medicine (2014)
FcRn is mother’s milk to allergen tolerance
Authors: Bart N. Lambrecht
Journal: The Journal of Experimental Medicine (2017)

In this issue Ohsaki et al. (https://doi.org/10.1084/jem.20171163) explain how breastfeeding can prevent the onset of food allergies in offspring by instructing T reg formation via neonatal Fc receptor (FcRn)–mediated transfer and uptake of allergen-containing IgG immune complexes (Ig-ICs) by gut dendritic cells (DCs).
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
Authors: R. Condorelli, L. Spring, J. O’Shaughnessy, L. Lacroix, C. Bailleux, V. Scott, J. Dubois, R.J. Nagy, R.B. Lanman, A.J. Iafrate, F. Andre, A. Bardia
Journal: Annals of Oncology (2017)
Abstract 17813: A DPP-4 Inhibitor, Anagliptin, Attenuates Both Fasting and Postprandial Hypertriglyceridemia
Authors: Masami Sairyo, Daisaku Masuda, Takuya Kobayashi, Kotaro Kanno, Hibiki Matsuda, Takeshi Okada, Tohru Ohama, Masahiro Koseki, Makoto Nishida, Yasushi Sakata, Shizuya Yamashita
Journal: Circulation (2016)

Introduction: The postprandial accumulation of intestine-derived chylomicrons (CMs) and chylomicron remnants (CM-Rs) is often observed in patients with diabetes mellitus. Since CM-Rs directly invad...
Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond
Authors: L. D’Ambrosio, G. Bothamley, J.A. Caminero Luna, R. Duarte, L. Guglielmetti, M. Muñoz Torrico, M.C. Payen, N. Saavedra Herrera, M.A. Salazar Lezama, A. Skrahina, M. Tadolini, S. Tiberi, N. Veziris, G.B. Migliori
Journal: Pulmonology (2017)

As recommended by the World Health Organization (WHO), optimal management of MDR-TB cases can be ensured by a multi-speciality consultation body known as 'TB Consilium'. This body usually includes different medical specialities, competences and perspectives (e.g., clinical expertise both for adults and children; surgical, radiological and public health expertise; psychological background and nursing experience, among others), thus lowering the risk of making mistakes – or managing the patients inappropriately, in order to improve their clinical outcomes. At present, several high MDR-TB burden countries in the different WHO regions (and beyond) have introduced TB Consilium-like bodies at the national or subnational level to reach consensus on the best treatment approach for their patients affected by TB. In addition, in countries/settings where a formal system of consultation does not exist, specialized staff from MDR-TB reference centres or international organizations usually spend a considerable amount of their working time responding to phone or e-mail clinical queries on how to manage M/XDR-TB cases. The aim of this manuscript is to describe the different experiences with the TB Consilia both at the international level (European Respiratory Society – ERS/WHO TB Consilium) and in some of the countries where this experience operates successfully in Europe and beyond. The Consilium experiences are described around the following topics: (1) history, aims and focus; (2) management and funding; (3) technical functioning and structure; (4) results achieved. In addition a comparative analysis of the TB Consilia in the different countries has been performed.
Trust fined £333 000 over the deaths of five patients from falls
Authors: Clare Dyer
Journal: BMJ (2017)

An NHS trust has been fined £333 000 (€379 000; $450 000) and ordered to pay £130 000 costs after it was prosecuted by the Health and Safety Executive for failing to protect five elderly patients who died after falls in hospital.

Mr Justice Haddon-Cave said Shrewsbury and Telford Hospital NHS Trust had inadequate risk assessment, handover procedures, and enhanced care arrangements in 2011 and 2012, when the patients had the falls.

He ruled that the trust’s failings were a significant cause or contributory factor in four of the five deaths: those …